Lupin Ltd has launched the first generic version of Pred Forte Ophthalmic Suspension USP, 1% in the US, targeting steroid-responsive eye inflammation. The company is entitled to 180 days of market exclusivity.
Lupin Ltd has launched the first generic version of Pred Forte Ophthalmic Suspension USP, 1% in the US, targeting steroid-responsive eye inflammation. The company is entitled to 180 days of market exclusivity.